|Bid||230.00 x 100|
|Ask||233.91 x 500|
|Day's Range||231.50 - 234.91|
|52 Week Range||115.40 - 234.91|
|PE Ratio (TTM)||105.16|
|Earnings Date||Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||205.80|
Failure to prosecute Alleged Multi-Year Accounting and Securities Fraud at Ligand Pharmaceuticals (NASDAQ: LGND) Diminishes SEC Credibility, Warrants Investigation MARLBOROUGH, Mass. , July 13, 2018 /PRNewswire/ ...
Ligand Pharmaceuticals Incorporated announced today plans to report second quarter 2018 financial results on August 6, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
In Q1 2018, Ligand Pharmaceuticals (LGND) incurred a cost of sales of $788,000 compared to $341,000 in Q1 2017. This increase was due to higher material sales in Q1 2018 compared to Q1 2017. The general and administrative expenses incurred by Ligand Pharmaceuticals increased marginally from $7.32 million in Q1 2017 to $7.64 million in Q1 2018.
Ligand Pharmaceuticals (LGND) has key partnerships with Novartis (NVS) for Promacta and Amgen (AMGN) for Kyprolis. In Q1 2018, Novartis generated $257 million from Promacta sales compared to $82 million in Q1 2017, an increase of 47%. In Q1 2018, Novartis announced that Promacta had received a breakthrough therapy designation from the FDA as a first-line therapy for use in combination with standard therapy for treating patients with severe aplastic anemia.
Ligand Pharmaceuticals (LGND) generates revenues from royalties, material sales, license fees, milestone payments, and other sources.
Ligand Pharmaceuticals (LGND) is engaged in developing and acquiring technologies for the development of medicines. Ligand Pharmaceuticals currently has partnerships and licensing agreements with more than 95 healthcare companies and more than 165 programs under license in different commercializations and stages of development. Two of the six analysts covering Ligand Pharmaceuticals in June gave the stock “strong buy” ratings, and four gave it “buy” ratings.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 28) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aptinyx Inc (NASDAQ: ...
NEW YORK, June 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EMCOR ...
Ligand Pharmaceuticals Incorporated (LGND) announces it has received $47 million as a result of signing an amendment relating to its OmniAb platform agreement with WuXi Biologics (“WuXi Bio”, SEHK: 2269.HK). This amendment provides WuXi Bio more efficiency in expanding its OmniAb antibody discovery services. Under the previous license agreement, OmniAb antibodies discovered and sub-licensed by WuXi Bio generated potential pre-defined contract payments to Ligand and potential royalties on global product sales.
This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)’s fundamentalsRead More...
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.
The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals
Kitov Pharma (KTOV) gained as the FDA approved Consensi (amlodipine and celecoxib) oral tablets for the treatment of osteoarthritis pain and hypertension.
Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.
The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.
Also, a slowdown in sales of some of the most high-profile older drugs, courtesy of payers and competitive pressure from both branded and generic drugs, is a concern for the sector. Drug pricing has been in the spotlight once again this month when President Donald Trump announced plans to lower prescription drug costs.
AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.